Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

By: Newsfile

Thailand's National Innovation-Mangosteen-Based Immunotherapy Fights HIV/AIDS

Bangkok, Thailand--(Newsfile Corp. - June 18, 2025) - The Operation BIM research team from Asian Phytoceuticals Public Company Limited, led by Professor Dr. Pichaet Wiriyachitra, has announced a significant achievement in immunotherapy innovation using Fortified Mangosteen Extracts. This natural formulation has helped 80 individuals living with HIV/AIDS reach a state known as "ByeByeHIV", characterized by strong health and, in some cases, the complete eradication of the virus from their bodies. The study has been published in the international journal Clinical Immunology Research under the title "ByeByeHIV with Thai Innovation."

Cannot view this image? Visit: https://images.newsfilecorp.com/files/8814/255952_45babc9eb467392b_002.jpg

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8814/255952_45babc9eb467392b_002full.jpg

According to the Ministry of Public Health, in 2025, Thailand is projected to have 8,862 new HIV cases, 10,217 people have died from AIDS-related conditions, while 568,565 individuals are living with HIV.

"ByeByeHIV" refers to a condition where HIV/AIDS patients can reduce their viral load to undetectable levels without the use of antiretroviral drugs (ARVs) while maintaining good health. It also applies to those who had adverse side effects from ARVs and can now discontinue treatment while staying healthy and HIV-undetectable.

The ByeByeHIV innovation is based on a natural extract formula composed of mangosteen, black sesame, soy, guava, and Centella asiatica. This dietary supplement, approved by the Thai FDA, boosts immune functions—especially Th1, Th17, and Killer T cells—targeting infected cells and repairing HIV- and ARV-induced telomere damage.

Based on the February 2024 publication titled "ByeByeHIV with Thai Innovation", (ByeByeHIV with Thai Innovation: https://www.scivisionpub.com/abstract-display.php?id=3167) the formula successfully helped two groups:

  • Group A: 24 HIV-positive individuals never on ARVs

  • Group B: 26 individuals previously treated with ARVs

By December 2024, both groups expanded to 40 participants each, all of whom achieved ByeByeHIV.

The latest journal article, ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A), reports all 40 participants in Group A achieved ByeByeHIV. Notably, 15 individuals stopped the mangosteen-based regimen for 6 months to over 4 years while maintaining undetectable viral loads and excellent health. The first participant to discontinue the formula has now been virus-free for nearly 10 years. This suggests complete HIV eradication for the 15 individuals.

The Group B study (Progress Update on 40 Cases with Prior Use of ARV Drugs) shows that all 40 participants also reached ByeByeHIV, with 15 discontinuing the regimen for 3 months to over 2 years—remaining healthy and HIV-free. This implies HIV/AIDS may now be curable without relapse.

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of

ARV Drugs (Group A) https://www.scivisionpub.com/abstract-display.php?id=3769

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of

ARV Drugs (Group B) https://www.scivisionpub.com/abstract-display.php?id=3770

These three remarkable recoveries highlight the potential of natural extract-based innovations in HIV treatment—restoring life quality to normalcy. All three individuals have publicly come forward and now serve as mentors, inspiring others to overcome stigma and reclaim their lives.

Professor Dr. Pichaet summarized, "This study confirms the potential of ByeByeHIV formula as a viable alternative for HIV patients unable to tolerate ARVs or new patients avoiding long-term ARV use. This marks a historic milestone for Thailand—challenging the 40-year belief that HIV/AIDS cannot be cured."

"This Thai national innovation deserves global recognition for safely awakening the body natural healing power without side effects. Though categorized as a supplement, it has achieved what pharmaceuticals could not. Legal frameworks should evolve to reflect modern scientific breakthroughs."

Contact Info:
Name: APCO Bangkok Office
Email: apco@apco.co.th
Organization: Asian Phytoceuticals Public Company Limited
Address: 30th Floor, AIA Capital Center, 89 Ratchadaphisek Road, Dindaeng District, Bangkok 10400, Thailand
Phone: 0-2646-4800
Website: https://www.apco.co.th

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255952

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.